Search Results
Your search for ,are matches 22257 pages
Showing 14001 - 14050Combating Untreated Cancer-Related Pain
The problem of pain management facing clinicians today is twofold: how to ensure safe and effective treatment for patients with cancer in chronic pain, while avoiding the overuse of opioid medications and the potential for substance use disorder and diversion. According to the American Cancer...
Expert Point of View: Frank Sinicrope, MD
Frank Sinicrope, MD, Professor of Medicine and Oncology at the Mayo Clinic, Rochester, Minnesota, told The ASCO Post that anti–programmed cell death protein 1 (anti–PD-1) agents “have already changed the landscape” of metastatic colorectal cancer. “We are currently treating microsatellite...
CheckMate 142 Update: Prolonged Disease Control With Nivolumab in Deficient Mismatch Repair Colorectal Cancer
With 6 additional months of follow-up since the initial presentation of results, in the phase II CheckMate 142 trial, 74% of heavily pretreated patients with metastatic colorectal microsatellite instability–high (MSI-H) cancers are alive after single-agent treatment with nivolumab (Opdivo).1...
Protein Component of the Epstein-Barr Virus May Promote the Development of Cancer
After an infection with the Epstein-Barr virus (EBV), the virus persists in the body throughout a person's lifetime, usually without causing any symptoms. About one-third of infected teenagers and young adults nevertheless develop infectious mononucleosis, which usually wears off after a few weeks. ...
Early Biomarker Algorithm May Predict Graft-vs-Host Disease Occurrence
Researchers at Mount Sinai Health System have discovered a way to predict whether patients with blood cancer who received a bone marrow transplant will develop graft-vs-host disease, according to a study published by Hartwell et al in JCI (The Journal of Clinical...
Combination of Alisertib and HSV1716 Shows Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor and Neuroblastoma Models
Two investigational agents, the aurora A kinase inhibitor alisertib and a virus derived from HSV-1 (HSV1716), have shown antitumor efficacy in early clinical trials as monotherapies. A new study published by Currier et al in Oncotarget, however, demonstrates that the combined usage...
Disease Symptoms Are the Most Frequent Indicators of Recurrence in Patients With Stage II Melanoma
Recurrences of early-stage (stage II) melanoma are more often detected by patients and their physicians than by routine imaging tests, according to study results published by Berger et al in the Journal of the American College of Surgeons. “We are most concerned about patients who have stage ...
Genetic Testing and Counseling Among Women With Newly Diagnosed Breast Cancer
In a population-based study reported in a research letter in JAMA, Kurian et al found that genetic testing and genetic counseling are suboptimal among women with newly diagnosed breast cancer. Study Details The study involved 2,451 women aged 20 through 79 years diagnosed with stage 0 to II...
2017 GU Cancers Symposium: In Advanced Kidney Cancer, Antibiotic Use Lowers Efficacy of Immunotherapy
A new retrospective analysis suggests that immunotherapy may be less effective in patients who receive antibiotics less than a month before starting treatment. In the study, cancer worsened more quickly in such patients than in those who did not receive antibiotics (with median progression-free...
2017 GU Cancers Symposium: Some Patients With Renal Cell Carcinoma Experience Long-Term Tumor Control Even After Stopping Immunotherapy Early
Early findings from a new study appear to challenge the current standard practice for immune checkpoint inhibitor therapy—continuing treatment until cancer worsens. Among patients with advanced kidney cancer who stopped programmed cell death protein 1/programmed cell death ligand 1...
2017 GU Cancers Symposium: Blood Test Uncovers Potential New Treatment Targets in Advanced Prostate Cancer
Analysis of free-floating cancer DNA from blood samples has yielded leads for new prostate cancer treatment targets. Using a commercially available “liquid biopsy” test in patients with advanced prostate cancer, researchers found a number of genetic changes in cell-free, circulating...
Clinical Trial Explores Ability of Genetic Test to Guide Surgical Management of Thyroid Cancer
University of Pittsburgh School of Medicine scientists and doctors are embarking on the first clinical trial to determine if a genetic test they pioneered could successfully spare patients with nonaggressive thyroid cancer from complete removal of their thyroid. Thyroid-preserving surgery minimizes ...
Patients With Breast Cancer With Dense Breast Tissue More Likely to Develop Contralateral Disease
Patients with breast cancer with dense breast tissue have almost a twofold increased risk of developing disease in the contralateral breast, according to new research from The University of Texas MD Anderson Cancer Center. The study, published by Brewster et al in the journal Cancer, is among the...
ASCP/CAP/AMP/ASCO Guideline on Molecular Biomarkers for Evaluation of Colorectal Cancer
As reported in the Journal of Clinical Oncology by Antonia Sepulveda, MD, PhD, of Columbia University, and colleagues, a joint guideline on the use of molecular biomarkers for evaluation of colorectal cancer has been developed by an expert panel from the American Society for Clinical Pathology...
Does Obesity Pose Risk for Transformation of Monoclonal Gammopathy of Undetermined Significance to Myeloma?
In a population-based cohort study reported in the Journal of the National Cancer Institute, Chang et al found that overweight and obesity were associated with an increased risk of transformation of monoclonal gammopathy of undetermined significance to multiple myeloma. Black race was also...
Adding Buparlisib to Paclitaxel in Platinum-Pretreated Squamous Cell Carcinoma of the Head and Neck
In the phase II BERIL-1 trial reported in The Lancet Oncology, Soulières et al found that adding the pan-PI3K (phosphatidylinositol 3-kinase) inhibitor buparlisib to paclitaxel improved outcomes in patients with platinum-pretreated recurrent metastatic squamous cell carcinoma of the head and ...
Researchers Identify ‘Synthetic Essentiality’ as Novel Approach for Locating Cancer Therapy Targets
A new method has been found for identifying therapeutic targets in cancers lacking specific key tumor suppressor genes. The process, which located a genetic site for the most common form of prostate cancer, has potential for developing precision therapy for other cancers, such as breast, brain, and ...
Most Patients Undergoing Elective Colorectal Surgery Receive Inadequate Bowel Preparation to Prevent Postoperative Complications
In the largest study of its kind to date, researchers from Fox Chase Cancer Center and the Lewis Katz School of Medicine at Temple University confirmed that oral antibiotics combined with mechanical bowel preparation were more effective at preventing surgical site infections...
Cancer Survivors Find Online and Telephone Communication With Health-Care Professionals Beneficial
Researchers from the School of Health Sciences at the University of Surrey have completed the first-ever systematic review of cancer survivors’ experience of online and telephone telehealth interventions in cancer care, a new study by Cox et al in the Journal of Medical Internet...
Children, Parents Overreport Leukemia Treatment Adherence
New research suggests that young patients with acute lymphocytic leukemia (ALL) and their parents are likely to report to their physician that they took more of their anticancer medication than they actually did. The study, published by Landier et al in Blood, found that 84% of patients with ALL...
ASCP/CAP/AMP/ASCO Clinical Practice Guideline Focuses on Molecular Biomarker Testing for Patients With Colorectal Cancer
A new, evidenced-based clinical practice guideline on molecular biomarker testing for patients with colorectal cancer identifies opportunities for improving patient outcomes. The American Society for Clinical Pathology (ASCP), the College of American Pathologists (CAP), the Association for...
Albert H. Owens, Jr, MD, Pioneering Johns Hopkins Oncologist, Dies
Albert H. Owens, Jr, MD, a Johns Hopkins oncologist who played a leadership role in developing oncology as a scientific discipline and clinical specialty—and who also served as President of The Johns Hopkins Hospital—died January 13 at the age of 90. In the 1960s, oncology was not a word that...
Co-Discoverer of the Philadelphia Chromosome, Peter Nowell, MD, Dies
Peter Nowell, MD, was a pathologist at the University of Pennsylvania studying leukemia cells under a microscope when he happened to wash his slides with tap water instead of laboratory solution. Viewing the newly cleaned slides under a microscope, he saw that the water had caused the cell’s...
I Plan to Live Long Enough to Be Cured of Multiple Myeloma
Like many other patients diagnosed with multiple myeloma, I didn’t know I had the cancer until I broke a bone. I had felt a twinge of pain on my left side when I hoisted a bucket of baseballs over my left shoulder after participating in a baseball tournament in the spring of 2011, but there was...
Kerry and Simone Vickar Family Foundation Commits $2 Million for Levine Cancer Institute Hematologic Oncology Chair
Carolinas HealthCare System has announced a $2 million commitment from the Kerry and Simone Vickar Family Foundation in support of academic and research efforts at the Levine Cancer Institute in Charlotte, North Carolina. The funds will be designated to establish an endowed chair in their name: The ...
Clinical Trials Actively Recruiting Patients With Cancer-Related Pain
Phase I Study Title: Qigong Mind-Body Exercise for Persistent Post-Surgical Pain in Breast Cancer Survivors: A Pilot Study Study Type: Phase I/interventional/single-group assignment Study Sponsor and Collaborators: Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Spaulding...
‘Collateral Lethality’ May Offer New Therapeutic Approach to Cancers of the Pancreas, Stomach, and Colon
Cancer cells often delete genes that normally suppress tumor formation. These deletions also may extend to neighboring genes, an event known as “collateral lethality,” which may create new options for the development of therapies for several cancers. Scientists at The University of Texas MD...
NCCN Working Group on Value Tools Presents Preliminary Findings and Recommendations
Over the past several years, the introduction of decision-making tools for patients from major cancer organizations, including ASCO and the National Comprehensive Cancer Network® (NCCN®), has been news, applauded as a step toward more patient-centered care and featured at many meetings. Next steps, ...
Telotristat Ethyl: A Novel Therapy for Carcinoid Syndrome—Not a Panacea but a Step in the Right Direction
The multihumoral manifestations of neuroendocrine tumors include diarrhea, cutaneous flushing, wheezing, and right-sided valvular heart disease.1 Serotonin, a biogenic amine and product of tryptophan metabolism,2 mediates several of these symptoms.3,4 Diarrhea is a cardinal and often disabling...
Telotristat Ethyl Reduces Frequency of Bowel Movements in Patients With Metastatic Neuroendocrine Tumors and Carcinoid Syndrome
In the phase III TELESTAR trial reported in the Journal of Clinical Oncology by Matthew H. Kulke, MD, of Dana-Farber Cancer Institute, and colleagues, telotristat ethyl, an investigational tryptophan hydroxylase inhibitor, significantly reduced the frequency of bowel movements in patients with...
Liquid Biopsies Show Promise in Diffuse Large B-Cell Lymphoma
Technologic advances for detecting and analyzing cell-free circulating tumor DNA (ctDNA) from peripheral blood offer a precision method for monitoring diffuse large B-cell lymphoma (DLBCL). Although most patients with DLBCL are cured with initial therapy, those who are not cured have a poor...
On the Horizon: New Tools for Prostate Cancer
The field of prostate cancer is being energized by discoveries in genetics, novel imaging techniques, and the potential of checkpoint inhibitors in the treatment of prostate cancer. Not all of these advances are currently clinically actionable, but all have the potential to change clinical...
Expert Point of View: Fiona Blackhall, PhD, FRCP
“There has undoubtedly been extremely rapid progress made in establishing effective therapies for anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC) patients in less than a decade,” said Fiona Blackhall, PhD, FRCP, Chair of Thoracic Oncology and medical oncologist at the...
ASCEND-4 Study Shows 45% Reduction in Risk of Disease Progression for NSCLC Patients on First-Line Ceritinib
Compared to chemotherapy, the use of first-line ceritinib (Zykadia) resulted in a statistically significant and clinically meaningful improvement in median progression-free survival, with an estimated 45% reduction in disease progression risk, as well as significant improvements in quality of...
Women of Indigenous Communities Prefer Self-Screening for Cervical Cancer
Cervical cancer is a preventable disease if detected on time, but it remains one of the leading causes of cancer deaths among women in Latin America, particularly women of poor and indigenous communities. A new study by the University of Michigan published by Gottschlich et al in the Journal of...
Patient Coaching and End-of-Life Discussions in Advanced Cancer
As reported by Rodenbach et al in the Journal of Clinical Oncology, a patient coaching session for patients with advanced cancer prior to an oncologist visit made it more likely that patients would discuss their prognosis during the visit. However, prognosis was still infrequently discussed. Study ...
Intentional Weight Loss in Postmenopausal Women May Be Linked to Reduced Endometrial Cancer Risk
Although many studies have linked obesity with an increased risk for endometrial cancer, information about the influence of weight loss on the cancer in postmenopausal women has been limited. Now, a study by Luo et al evaluating the association of weight change and endometrial cancer risk among...
Nearly Half of Patients Treated for Early-Stage Breast Cancer Report at Least One Severe Side Effect
Nearly half of women treated for early-stage breast cancer reported at least one side effect from their treatment that was severe or very severe, according to a new study published by Friese et al in Cancer. Although it might be expected for women undergoing chemotherapy, researchers found...
FDA Accepts Two sBLAs for Pembrolizumab in Locally Advanced or Metastatic Urothelial Cancer
On February 3, the U.S. Food and Drug Administration (FDA) accepted for review two supplemental Biologics License Applications (sBLAs) for pembrolizumab (Keytruda) in patients with locally advanced or metastatic urothelial cancer. Specifically, the application for first-line use was accepted and...
Expert Point of View: Michael Boyer, MBBS, PhD
“This drug [durvalumab] clearly shows activity in the third-line and beyond setting, and the higher the programmed cell death ligand 1 (PD-L1) expression, the higher the response rate,” noted Michael Boyer, MBBS, PhD, Chief Clinical Officer and Conjoint Chair of Medical Oncology (Thoracic...
Study Finds Durvalumab of Benefit in Advanced and Metastatic Non–Small Cell Lung Cancer
Durvalumab was active and led to long-lasting response in a cohort of heavily pretreated patients with epidermal growth factor receptor/anaplastic lymphoma kinase (EGFR/ALK) wild-type locally advanced and metastatic non–small cell lung cancer (NSCLC), particularly among patients whose tumors...
ASCO Releases Principles for Patient-Centered Health-Care Reform
ASCO has released “ASCO Principles for Patient-Centered Health-Care Reform,” seven recommendations designed to ensure access to high-quality cancer care amid the changing U.S. health-care delivery landscape. The principles aim to assist the new Congress and Administration, so, as they consider the...
From Azerbaijan to America: An IDEA Recipient’s Experience
Cancer takes away millions of lives every year, and in low- and middle-income countries, the high cancer mortality rate can often be attributed to scarce means and a shortage of trained professionals. Hoping to contribute my best in the fight against this disease, I chose to become an oncologist in ...
Growing Leadership Development Program Tasks Participants With Increasing Society Engagement
The 2016–2017 ASCO Leadership Development Program recently welcomed 16 new participants to its ranks. The Leadership Development Program is a yearlong program designed to shape future leaders by teaching them valuable leadership skills and providing them with networking and mentorship opportunities ...
Early Success Reported With Two New Agents for High-Risk Myelodysplastic Syndromes
At the 2016 American Society for Hematology (ASH) Annual Meeting & Exposition, researchers reported early success with two new experimental agents for high-risk myelodysplastic syndromes—enasidenib (also known as AG-221), a potent oral inhibitor of the isocitrate dehydrogenase 2 (IDH2) enzyme,...
Selected Abstracts From the 2016 ASH Annual Meeting
Here are several abstracts selected from the proceedings of this year’s American Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics in several different types of non-Hodgkin lymphomas (NHLs), including mantle cell lymphoma and marginal zone lymphoma. For...
Expert Point of View: Stephen Ansell, MD, PhD
Stephen Ansell, MD, PhD, Chair of the Mayo Clinic Lymphoma Group, said the “exciting results” of these studies indicated that “we have come a long way in Hodgkin lymphoma.” “It’s been very gratifying to see that the excellent initial trial results with the anti–programmed cell death protein 1...
Studies Advance the Use of PD-1 Blockade in Classical Hodgkin Lymphoma
Classical Hodgkin lymphoma is one of the malignancies most susceptible to treatment with monoclonal antibodies targeting the programmed cell death protein (PD-1). Nivolumab (Opdivo) has been approved by the U.S. Food and Drug Administration (FDA) for use in patients with relapsed/refractory...
Autologous Breast Reconstruction Associated With Fewer Complications and Failures Than Implants in Women Who Have Received Radiation
Postmastectomy radiation is becoming more commonly used to treat breast cancer, and at the same time, there is an increasing trend among women to have breast reconstruction. Until now, oncologists have had little evidence on what the best reconstruction options are in women who require radiation...
Expert Point of View: Virginia Kaklamani, MD, and Melinda L. Telli, MD
Moderator of the press conference on this study, Virginia Kaklamani, MD, of the University of Texas Health Science Center at San Antonio, agreed that an improvement in response is important. “If you are a patient with symptoms, such as a cough from lung metastases, and I give you a combination...
